<div id="readability-page-1"><ul><li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li></ul><p>Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) - Analysts at Lifesci Capital raised their FY2025 earnings estimates for Centessa Pharmaceuticals in a research report issued on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.39). Lifesci Capital currently has a &#34;Strong-Buy&#34; rating on the stock. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals' Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.</p><p>A number of other equities analysts have also weighed in on CNTA. Wall Street Zen raised Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price target on the stock. Chardan Capital  reissued a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Truist Financial  set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, November 5th. One equities research analyst  has rated the stock with a Strong Buy rating, ten have assigned  a Buy rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.11.</p><p><b>Check Out Our Latest Analysis on CNTA</b></p><h2>Centessa Pharmaceuticals Price Performance</h2><p>CNTA stock opened at $27.61 on Monday. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The firm has a market capitalization of $3.70 billion, a PE ratio of -15.09 and a beta of 1.56. The business has a 50 day simple moving average of $23.17 and a 200-day simple moving average of $17.56. </p><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). </p><h2>Insider Activity at Centessa Pharmaceuticals</h2><p>In related news, insider Mario Alberto Accardi sold 8,000 shares of the business's stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the sale, the insider owned 194,394 shares in the company, valued at approximately $4,859,850. The trade was a 3.95% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 179,964 shares of company stock worth $4,106,481. Insiders own  7.09% of the company's stock. </p><h2>Institutional Trading of Centessa Pharmaceuticals</h2><p>Several hedge funds have recently made changes to their positions in CNTA. Avoro Capital Advisors LLC boosted its stake in shares of  Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company's stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the period.  Adage Capital Partners GP L.L.C. lifted its holdings in  Centessa Pharmaceuticals by 35.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company's stock worth $99,999,000 after buying an additional 1,834,973 shares in the last quarter.  Federated Hermes Inc. purchased a new position in  Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000.  Balyasny Asset Management L.P. acquired a new position in shares of  Centessa Pharmaceuticals in the second quarter worth $16,052,000.  Finally, Commodore Capital LP increased its position in shares of  Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company's stock worth $43,340,000 after acquiring an additional 930,711 shares during the period. Institutional investors and hedge funds own  82.01% of the company's stock. </p><h2>Centessa Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p><h2>See Also</h2><ul><li>Five stocks we like better than Centessa Pharmaceuticals</li><li>Insider Selling Explained: Can it Inform Your Investing Choices?</li><li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li><li>A Deeper Look at Bid-Ask Spreads</li><li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTA

<p>Lifesci Capital has raised its FY2025 earnings estimates for Centessa Pharmaceuticals, now expecting an EPS of ($1.37), up from ($1.39). The firm maintains a "Strong-Buy" rating on the stock. Centessa's stock has a consensus target price of $33.11, with an average rating of "Moderate Buy." Recent insider trading and institutional investments indicate significant interest in the company. The stock opened at $27.61, with a market cap of $3.70 billion.</p>

Lifesci Capital Issues Optimistic Forecast for CNTA Earnings